GlassScriptPhysician profile
Adam M Vargo
NPI 1861683187
$1,389.08
in general payments reported to CMS, 2019-2025
24 companies · $626 in 2025
The $626 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.20 · 2022: $31.94 · 2023: $110 · 2024: $592 · 2025: $626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,327.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $251.76 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $196.22 | 2023-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $136.63 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $124.82 | 2019-2025 | |
| Novo Nordisk INC | $92.89 | 2019-2025 | Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $83.81 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Phathom Pharmaceuticals, INC. | $71.71 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $66.20 | 2025 | Gemtesa |
| Lundbeck LLC | $45.13 | 2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $34.97 | 2024 | |
| Abbott Laboratories | $30.70 | 2024 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $29.28 | 2024 | Eliquis, Camzyos |
| Seqirus USA INC | $24.61 | 2024 | Fluad, Flucelvax |
| Otsuka America Pharmaceutical, INC. | $24.32 | 2023 | Rexulti |
| Astellas Pharma US INC | $24.07 | 2024 | Veozah |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $22.09 | 2025 | Brixadi |
| Mylan Specialty L.P. | $21.36 | 2024 | Yupelri |
| Exact Sciences Corporation | $20.57 | 2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $19.65 | 2024 | Xarelto |
| Verona Pharma, INC. | $16.69 | 2025 | Ohtuvayre |
| Vertex Pharmaceuticals Incorporated | $15.19 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.09 | 2023 | Jardiance, Tradjenta |
| Dexcom, INC. | $13.21 | 2022 | |
| Axsome Therapeutics, INC. | $9.11 | 2025 | Sunosi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Vargo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.